Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0657 | 0.9358 | 0.9549 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0062 | 0.0196 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.0386 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.5 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 0.181 | 0.3572 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Schistosoma mansoni | protein tyrosine phosphatase non-receptor type nt1 | 0.0378 | 0.5066 | 1 |
Brugia malayi | Protein-tyrosine phosphatase containing protein | 0.0378 | 0.5066 | 0.5244 |
Echinococcus granulosus | tyrosine protein phosphatase non receptor type | 0.0378 | 0.5066 | 1 |
Echinococcus multilocularis | tyrosine protein phosphatase non receptor type | 0.0378 | 0.5066 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0263 | 0.3292 | 1 |
Brugia malayi | nuclear hormone receptor | 0.0677 | 0.9661 | 1 |
Loa Loa (eye worm) | protein-tyrosine phosphatase | 0.0378 | 0.5066 | 0.3153 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0182 | 0.2043 | 0.1027 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0177 | 0.1973 | 0.3649 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.5 |
Onchocerca volvulus | Glucosylceramidase homolog | 0.0173 | 0.19 | 0.19 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.0386 |
Loa Loa (eye worm) | O-glycosyl hydrolase family 30 protein | 0.0263 | 0.3292 | 0.0509 |
Brugia malayi | O-Glycosyl hydrolase family 30 protein | 0.0263 | 0.3292 | 0.3407 |
Loa Loa (eye worm) | nuclear receptor nhr-7B | 0.0677 | 0.9661 | 1 |
Trichomonas vaginalis | glucosylceramidase, putative | 0.0182 | 0.2043 | 0.1027 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0155 | 0.1634 | 0.2953 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.5 |
Brugia malayi | hypothetical protein | 0.0241 | 0.295 | 0.3054 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0177 | 0.1973 | 0.3895 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0062 | 0.0196 | 0.5 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0241 | 0.295 | 0.5656 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0241 | 0.295 | 0.5656 |
Trypanosoma brucei | RNA helicase, putative | 0.0167 | 0.181 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV V179E mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV G190A mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV G190S mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV F227C mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV L100I and K103N mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV K101E and K103N mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration value against HIV K103N and Y181C mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV F227L and V106A mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | 0 uM | In vitro inhibitory concentration against HIV Y188L mutant strain ;not determined | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV L100I mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV K101E mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV V106A mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0 uM | In vitro inhibitory concentration against HIV E138K mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 0.126 uM | In vitro inhibitory concentration against HIV LAI cell line | ChEMBL. | 15771439 |
IC50 (binding) | = 0.126 uM | Inhibition of HIV1 reverse transcriptase in human LAI cells | ChEMBL. | 18410080 |
IC50 (binding) | = 0.126 uM | Inhibition of HIV1 reverse transcriptase | ChEMBL. | 18410085 |
IC50 (functional) | = 1.995 uM | In vitro inhibitory concentration against HIV K103N mutant strain | ChEMBL. | 15771439 |
IC50 (functional) | = 5.012 uM | In vitro inhibitory concentration against HIV-1 Y181C mutant strain | ChEMBL. | 15771439 |
SI (functional) | = 398 uM | Selective index value (ratio of CC50 to IC50 value)against HIV LAI cell line | ChEMBL. | 15771439 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.